Rochester Drug Co-Operative, Inc., et al. v. Braintree Labs, Inc., No. 07-142 (D. Del.)

In this case, nicknamed the MiraLax case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a settlement class of direct purchasers of Braintree’s branded drug, MiraLax (polyethylene glycol 3350).  The case alleges that Braintree, to forestall competition from less-expensive generic versions of MiraLax, hatched an anticompetitive scheme that included a wrongful listing of a patent in the FDA Orange Book and sham litigation, thereby violating § 2 of the Sherman Act.  The case alleges that Braintree’s scheme permitted it to charge Plaintiffs and members of the class artificially inflated prices for their purchases of brand and generic MiraLax.  A settlement in the amount of $17.25 million was reached in 2012.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.


Filed on 03/12/2007


1617 JFK Boulevard, Suite 1550

19103 Philadelphia, Pennsylvania

Phone (215) 277-5770

Fax (215) 277-5771


Peter Kohn Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331


10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885


3565 Piedmont Road NE Building Four, Suite 380
Atlanta, Georgia 30305
(404) 847-0617
(404) 506-9534


1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania